Pfizer said Monday its research shows its product works for children aged five to 11 and that it will also seek U.S. authorization for this age group soon — a key step toward protecting schoolchildren from the novel coronavirus.
Pfizer said Monday its research shows its product works for children aged five to 11 and that it will also seek U.S. authorization for this age group soon — a key step toward protecting schoolchildren from the novel coronavirus.
